Safety and efficacy of ustekinumab in the treatment of Crohn Disease: a systematic review and meta-analysis
J. coloproctol. (Rio J., Impr.)
;
42(2): 178-186, Apr.-June 2022. graf, ilus
Article
Dans Anglais
| LILACS
| ID: biblio-1394409
ABSTRACT
ABSTRACT Background and Aims The present systematic review and meta-analysis was designed to estimate the safety and effectiveness of ustekinumab in the treatment of Crohn disease (CD) in clinical trials and observational studies. Methods We retrieved all the related publications from the PubMed, Cochrane, EBSCO, Google Scholar and EMBASE databases using a systematic search strategy. We only included clinical trials and observational studies that were published in English. Results Only 31 studies that met the eligibility criteria out of the 733 identified studies were included. The overall clinical response rate in the cohort studies was of 0.539 (95% confidence interval [95%CI] 0.419-0.659), and in the clinical trials it was of 0.428 (95%CI 0.356-0.501). The pooled clinical remission rate was of 0.399 (95%CI 0.295-0.503) in randomized control trials (RCTs,) and of 0.440 (95%CI 0.339-0.542) in cohort studies. The rate of adverse effects was of 0.158 (95%CI 0.109-0.207) in cohort studies and of 0.690 (95%CI 0.633-0.748) in RCTs. Conclusion Ustekinumab is effective in the treatment of CD. However, more research is required on the safety profiles because there was considerable variation among the included studies. (AU)
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Maladie de Crohn
/
Ustékinumab
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
/
Étude pronostique
/
Revues systématiques évaluées
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
J. coloproctol. (Rio J., Impr.)
Thème du journal:
Cirurgia
/
Doenas Retais
/
Doenas do Colo
/
Gastroentérologie
/
Cirurgia
Année:
2022
Type:
Article
Pays d'affiliation:
Égypte
Institution/Pays d'affiliation:
Cairo University/EG
/
Crohn's & Colitis Egypt Center/EG
/
Tanta University/EG
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS